+1 Recommend
2 collections
      • Record: found
      • Abstract: found
      • Article: not found

      Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Dear Editor, Since early December 2019, a large outbreak of pneumonia caused by a novel coronavirus (COVID-19) had emerged in Wuhan, China (Wu et al. 2020a, b; Zhou et al. 2020; Zhu et al. 2020; Jiang and Shi 2020). Similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), the new coronavirus also belongs to Betacoronavirus, and shares highest sequence identity to three SARS-like CoVs of bat origin (bat_CoV_RaTG13: 96.0%, bat-SL-CoVZC45: 88.0% and bat-SL-CoVZXC21: 87.2%) (Zhou et al. 2020). Although only sharing about 79.5% genomic sequence identity to SARS-CoV, the new virus was demonstrate to use the same receptor angiotensin converting enzyme II (ACE2) for human infection as SARS-CoV (Lu et al. 2020; Wu 2020; Zhou et al. 2020) and is officially named as SARS-CoV-2 (also known as 2019-nCoV) (Gorbalenya et al. 2020). Epidemically data showed that the virus has strong human-to-human transmission ability, and it is spread by droplets produced by coughing and sneezing, infecting susceptible subjects through direct contacts and other possible transmission routes (e.g. fecal-mouth transmission) (Guan et al. 2020; Li et al. 2020). As of Mar. 27, 2020, the outbreak had resulted in 533,464 laboratory-confirmed cases, including 24,097 deaths around the world. Currently, there lacks suitable antiviral drugs or vaccines for SARS-CoV-2. Early, rapid, and reliable diagnostic assays for SARS-CoV-2 is of top priority to facilitate public health interventions that can reduce or avoid further spread of SARS-CoV-2 (Dennis Lo and Chiu 2020). Quantitative Real-time PCR (qPCR) is a robust technology for reliable laboratory diagnosis, and routinely used to detect causative pathogens. Since the release of genomic sequence of SARS-CoV-2 in Jan. 11, 2020, many TaqMan probe-based RT-qPCR assays had been developed and used in confirmation of large number of SARS-CoV-2 infections during the outbreak (Chu et al. 2020; Dennis Lo and Chiu 2020). Facing the on-going increase of suspected cases and potential contacts, however, the detection capacity of RT-qPCR assays have shown limitations in speed and volume because these assays require sophisticated equipment and highly trained personnel, and are relatively time-consuming (about 1.5–2 h). Therefore, there is an urgent demand for faster and sensitive Point-of-Care testing (POCT) assays to facilitate rapid detection of SARS-CoV-2 infection. However, there is no POCT assay available for SARS-CoV-2 yet. Here, we present a novel visual reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for rapid and sensitive detection of SARS-CoV-2 using mismatch-tolerant technique. Based on SARS-CoV-2 genomic sequences, we designed six sets of LAMP primers (4, 1, and 1 in N, S and RdRp genes, respectively) using the open access Primer Explorer V.5 software tool ( We firstly excluded primer sets with non-specific amplification, and then selected the primers having high amplification efficiency using the conventional RT-LAMP method. The RdRp primers showed higher amplification efficiency, and were selected to establish the SARS-CoV-2 detection assay using the mismatch-tolerant RT-LAMP method (Li et al. 2019; Zhou et al. 2019). The RdRp primer information is shown in Fig. 1A, 1B. A 25 µL reaction system includes 1 × isothermal amplification buffer, 6 mmol/L MgSO4, 1.4 mmol/L dNTPs, 8 units of WarmStart Bst 3.0 DNA polymerase, 7.5 units of WarmStartR RT, 0.15 unit of Q5 High-Fidelity DNA Polymerase, 1.6 μmol/L each of primers of FIP and BIP, 0.2 μmol/L each of primers of F3 and B3, 0.8 μmol/L of loop primer FLP and BLP, and 0.4 mmol/L SYTO 9 (Life technologies, Carlsbad, CA, United States). Three types of polymerases were purchased from New England Biolabs (Beverly, MA, United States). Three microliters of RNA were used for the RT-LAMP assays. The RT-LAMP reaction was performed at 63 °C for 50 min for real-time monitoring using the Light Cycler 96 real-time PCR System (Roche Diagnostics, Mannheim, Germany). Fig. 1 A Location of the primers in SARS-CoV-2 genome. B Sequence comparison among seven human coronaviruses (SARS-CoV2, SARS-CoV, MERS-CoV, OC43, HKU1, NL63 and 229E). C Cross-reactivity test of the novel SARS-CoV-2 RT-LAMP assay to other common respiratory viruses. Tested common respiratory viruses include HCoV-HKU-1, HCoV-NL63, HCoV-OC43, HCoV-229E, influenza A, B, and C viruses, parainfluenza viruses type 1–3, enterovirus, respiratory syncytial virus A and B groups, human rhinovirus, human metapneumovirus, adenovirus and bocavirus. RNA from a COVID-19 patient was used as positive control (PC). NTC, non-template control. D Sensitivity test of the novel SARS-CoV-2 RT-LAMP assay. Positive amplification was defined only when all three replicates are successfully amplified. NTC: non-template control. E Visual detection of SARS-CoV-2 by the colorimetric RT-LAMP assay. E-a RNA standards; E-b Clinical samples. NTC: non-template control. To determine the specificity of the SARS-CoV-2 RT-LAMP assay, 15 clinical samples positive for common respiratory viruses (including influenza A, B, and C viruses, parainfluenza viruses type 1–3, enterovirus, respiratory syncytial virus (RSV) A and B groups, HCoV-HKU-1, HCoV-NL63, human rhinovirus, human metapneumovirus, adenovirus and bocavirus), and two human coronavirus standard strains HCoV-OC43 (VR-1558) and HCoV-229E (VR-740) were tested. None or very weak amplification signals were observed for all 17 respiratory viruses after 50 min, indicating good specificity of the assay (Fig. 1C). Although we did not test the specificity for SARS-CoV and MERS-CoV because of the lack of clinical samples or standard strains, the sequence comparison suggests the RT-LAMP can also amplify SARS-CoV due to high sequence similarity (Fig. 1B). To prepare RNA standard, a SARS-CoV-2 RdRp fragment (15,034–15,274 nt in Wuhan-Hu-1, GenBank: MN908947.3) was amplified from positive clinical sample with T7-promoter-containing primers, and then the products were subjected to in vitro transcription. RNA products were quantitated by Nanodrop 2000C (Thermo, USA). A tenfold serial dilution of RNA standard from 106 to 1 copies per μL was used to test the sensitivity of the SARS-CoV-2 RT-LAMP assay. The result showed that the RT-LAMP can detect as few as 3 copies of SARS-CoV-2 RNA per 25 μL reaction (Fig. 1D). In particular, amplification curves of template inputs > 300 copies appeared within 20 min, showing a fast amplification (Fig. 1D). For the POCT diagnosis of SARS-CoV-2 infection in the resource-poor settings, we developed the assay into a visual detection using WarmStart Colorimetric LAMP 2 × Master Mix (New England Biolabs, Beverly, MA, United States). A 25 µL reaction system includes 1 × WarmStart Colorimetric LAMP buffer, 0.15 unit of Q5 High-Fidelity DNA Polymerase, 1.6 μmol/L each of primers of FIP and BIP, 0.2 μmol/L each of primers of F3 and B3, and 0.8 μmol/L of loop primer FLP and BLP. The reactions were performed at 63 °C, and the color change was observed at the 30-, 40-, and 50-min time points. The visual detection system contains a pH-sensitive indicator dye cresol red. Because LAMP amplification results in a significant pH change of buffer from an initial alkaline condition to a final acidic condition (Tanner et al. 2015), the color change of cresol red from burgundy to orange or yellow indicates a positive reaction. The assay gave a clear color indication for all tested samples during 30–50 min (data not shown). We selected 40 min as the cut-off for the visual assay (Fig. 1E). The sensitivity of the colorimetric RT-LAMP assay for SARS-CoV-2 was 30 copies per reaction, slightly lower than the real-time monitoring (Fig. 1E). To evaluate the performance of the colorimetric RT-LAMP assay for SARS-CoV-2, we compared it with the SARS-CoV-2 RT-qPCR kit (Liferiver Bio, Shanghai, China) using 24 clinical samples. All 17 positive samples as shown by the RT-qPCR assay (CT values: 28.8–40) were also positive by the novel RT-LAMP assay, demonstrating a 100% consistency (Supplementary Table S1). The severity of SARS-CoV-2 pandemic had exceeded SARS-CoV. In Jan. 30, 2020, The COVID-19 pandemic was declared as a public health emergency of international concern by WHO. Early diagnosis and timely implementation of intervention and quarantine measures are very crucial for prevention and control of emerging infectious diseases such as COVID-19 (Dennis Lo and Chiu 2020). The rapid identification of SARS-CoV-2 and subsequent release of its genome sequence are very important in a public health perspective, and these made the development of SARS-CoV-2 diagnostic assays possible. Many RT-qPCR assays have been developed and used in the confirmation of SARS-CoV-2 infection during the pandemic (Chu et al. 2020). However, high level facility requirement of RT-qPCR assays is a major factor limiting the confirmation speed and causing a large number of suspected cases waiting for tests as these assays are not available in primary care and community hospitals or health care centers where there were no real-time thermal cycler and trained professional. On the other hand, the median incubation period of COVID-19 is 4 days (range 0–24.0 days), and the longest incubation period observed is 24 days (Guan et al. 2020). In particular, some infected individuals did not develop obvious clinical symptoms (Rothe et al. 2020). The long incubation period and asymptomatic infections imply a huge risk of virus transmission to other people (Wu et al. 2020a, b). In this respect, POCT detection tools that can be performed in fields and even patients’ own houses have a huge advantage, and should be developed. LAMP is the most commonly used isothermal amplification technique for POCT diagnosis due to its high sensitivity, rapid reaction, simple operation, and easy observation of results. Recently, we developed a mismatch-tolerant LAMP method by adding 0.15 U of high-fidelity DNA polymerase (Zhou et al. 2019). The main difference between the mismatch-tolerant LAMP and the conventional ones is the inclusion of an additional amount of high-fidelity DNA polymerase in the former, which largely improves the sensitivity and reaction speed (Li et al. 2019; Zhou et al. 2019). Using this mismatch-tolerant technique, we developed a one-step single-tube RT-LAMP assay for detection of SARS-CoV-2. The assay can be performed at 63 °C for 40 min in a real-time or a regular thermal cycler, or any heating block such as a dry incubator or a water bath. The result is easily judged by the color change from burgundy to orange or yellow. Compared to the conventional LAMP protocol, the novel SARS-CoV-2 RT-LAMP assay is more rapid and more sensitive. The sensitivity of the assay is 30 copies per reaction. Although we did not test the specificity for SARS-CoV and MERS-CoV due to a lack of clinical samples, we sound the assay exhibited specificity by testing 17 common human respiratory viruses, including four other human coronaviruses OC43, 229E, HKU-1 and NL63. The evaluation with 24 clinical samples showed that all 17 COVID-19 patients in Nantong city were positive for SARS-CoV-2 by both the RT-LAMP and the RT-qPCR assays, showing a full consistence. In conclusion, the novel visual RT-LAMP assay is a simple, rapid, and sensitive approach for detection of SARS-CoV-2, and it is ready for application in primary care and community hospitals or health care centers, and even patients’ own houses in response to the current SARS-CoV-2 epidemic because the assay does not require sophisticated equipment and skilled personnel. Furthermore, it is also ready to be used in fields for screening samples from wild animals and environments to facilitate the identification of potential intermediate hosts that mediate the cross-species transmission of SARS-CoV-2 from bats to humans. í supplementary material Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 75 kb)

          Related collections

          Most cited references 16

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical Characteristics of Coronavirus Disease 2019 in China

          Abstract Background Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of the affected patients. Methods We extracted data regarding 1099 patients with laboratory-confirmed Covid-19 from 552 hospitals in 30 provinces, autonomous regions, and municipalities in mainland China through January 29, 2020. The primary composite end point was admission to an intensive care unit (ICU), the use of mechanical ventilation, or death. Results The median age of the patients was 47 years; 41.9% of the patients were female. The primary composite end point occurred in 67 patients (6.1%), including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who died. Only 1.9% of the patients had a history of direct contact with wildlife. Among nonresidents of Wuhan, 72.3% had contact with residents of Wuhan, including 31.3% who had visited the city. The most common symptoms were fever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%). Diarrhea was uncommon (3.8%). The median incubation period was 4 days (interquartile range, 2 to 7). On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT) (56.4%). No radiographic or CT abnormality was found in 157 of 877 patients (17.9%) with nonsevere disease and in 5 of 173 patients (2.9%) with severe disease. Lymphocytopenia was present in 83.2% of the patients on admission. Conclusions During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness. Patients often presented without fever, and many did not have abnormal radiologic findings. (Funded by the National Health Commission of China and others.)
            • Record: found
            • Abstract: found
            • Article: not found

            Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

             Qun Li,  Xuhua Guan,  Peng Wu (2020)
            Abstract Background The initial cases of novel coronavirus (2019-nCoV)–infected pneumonia (NCIP) occurred in Wuhan, Hubei Province, China, in December 2019 and January 2020. We analyzed data on the first 425 confirmed cases in Wuhan to determine the epidemiologic characteristics of NCIP. Methods We collected information on demographic characteristics, exposure history, and illness timelines of laboratory-confirmed cases of NCIP that had been reported by January 22, 2020. We described characteristics of the cases and estimated the key epidemiologic time-delay distributions. In the early period of exponential growth, we estimated the epidemic doubling time and the basic reproductive number. Results Among the first 425 patients with confirmed NCIP, the median age was 59 years and 56% were male. The majority of cases (55%) with onset before January 1, 2020, were linked to the Huanan Seafood Wholesale Market, as compared with 8.6% of the subsequent cases. The mean incubation period was 5.2 days (95% confidence interval [CI], 4.1 to 7.0), with the 95th percentile of the distribution at 12.5 days. In its early stages, the epidemic doubled in size every 7.4 days. With a mean serial interval of 7.5 days (95% CI, 5.3 to 19), the basic reproductive number was estimated to be 2.2 (95% CI, 1.4 to 3.9). Conclusions On the basis of this information, there is evidence that human-to-human transmission has occurred among close contacts since the middle of December 2019. Considerable efforts to reduce transmission will be required to control outbreaks if similar dynamics apply elsewhere. Measures to prevent or reduce transmission should be implemented in populations at risk. (Funded by the Ministry of Science and Technology of China and others.)
              • Record: found
              • Abstract: found
              • Article: not found

              Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

              To the Editor: The novel coronavirus (2019-nCoV) from Wuhan is currently causing concern in the medical community as the virus is spreading around the world. 1 Since identification of the virus in late December 2019, the number of cases from China that have been imported into other countries is on the rise, and the epidemiologic picture is changing on a daily basis. We are reporting a case of 2019-nCoV infection acquired outside Asia in which transmission appears to have occurred during the incubation period in the index patient. A 33-year-old otherwise healthy German businessman (Patient 1) became ill with a sore throat, chills, and myalgias on January 24, 2020. The following day, a fever of 39.1°C (102.4°F) developed, along with a productive cough. By the evening of the next day, he started feeling better and went back to work on January 27. Before the onset of symptoms, he had attended meetings with a Chinese business partner at his company near Munich on January 20 and 21. The business partner, a Shanghai resident, had visited Germany between January 19 and 22. During her stay, she had been well with no signs or symptoms of infection but had become ill on her flight back to China, where she tested positive for 2019-nCoV on January 26 (index patient in Figure 1) (see Supplementary Appendix, available at, for details on the timeline of symptom development leading to hospitalization). On January 27, she informed the company about her illness. Contact tracing was started, and the above-mentioned colleague was sent to the Division of Infectious Diseases and Tropical Medicine in Munich for further assessment. At presentation, he was afebrile and well. He reported no previous or chronic illnesses and had no history of foreign travel within 14 days before the onset of symptoms. Two nasopharyngeal swabs and one sputum sample were obtained and were found to be positive for 2019-nCoV on quantitative reverse-transcriptase–polymerase-chain-reaction (qRT-PCR) assay. 2 Follow-up qRT-PCR assay revealed a high viral load of 108 copies per milliliter in his sputum during the following days, with the last available result on January 29. On January 28, three additional employees at the company tested positive for 2019-nCoV (Patients 2 through 4 in Figure 1). Of these patients, only Patient 2 had contact with the index patient; the other two patients had contact only with Patient 1. In accordance with the health authorities, all the patients with confirmed 2019-nCoV infection were admitted to a Munich infectious diseases unit for clinical monitoring and isolation. So far, none of the four confirmed patients show signs of severe clinical illness. This case of 2019-nCoV infection was diagnosed in Germany and transmitted outside Asia. However, it is notable that the infection appears to have been transmitted during the incubation period of the index patient, in whom the illness was brief and nonspecific. 3 The fact that asymptomatic persons are potential sources of 2019-nCoV infection may warrant a reassessment of transmission dynamics of the current outbreak. In this context, the detection of 2019-nCoV and a high sputum viral load in a convalescent patient (Patient 1) arouse concern about prolonged shedding of 2019-nCoV after recovery. Yet, the viability of 2019-nCoV detected on qRT-PCR in this patient remains to be proved by means of viral culture. Despite these concerns, all four patients who were seen in Munich have had mild cases and were hospitalized primarily for public health purposes. Since hospital capacities are limited — in particular, given the concurrent peak of the influenza season in the northern hemisphere — research is needed to determine whether such patients can be treated with appropriate guidance and oversight outside the hospital.

                Author and article information

                Virol Sin
                Virol Sin
                Virologica Sinica
                Springer Singapore (Singapore )
                1 April 2020
                : 1-4
                [1 ]GRID grid.260483.b, ISNI 0000 0000 9530 8833, Clinical Laboratory, , Nantong Third Hospital Affiliated to Nantong University, ; Nantong, 226006 China
                [2 ]GRID grid.429007.8, ISNI 0000 0004 0627 2381, Pathogen Discovery and Evolution Unit, , Institut Pasteur of Shanghai, Chinese Academy of Sciences, ; Shanghai, 200031 China
                [3 ]GRID grid.490502.a, Medical Laboratory of Taizhou Fourth People’s Hospital, ; Taizhou, 225300 China
                [4 ]GRID grid.462338.8, ISNI 0000 0004 0605 6769, College of Life Sciences, , Henan Normal University, ; Xinxiang, 453007 China
                [5 ]GRID grid.8547.e, ISNI 0000 0001 0125 2443, Shanghai Public Health Clinical Center, , Fudan University, ; Jinshan District, Shanghai, 201508 China
                © Wuhan Institute of Virology, CAS 2020

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.



                Comment on this article